ABI-009, an mTOR Inhibitor, for Patients With Severe Pulmonary Arterial Hypertension
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
mTOR activation has been shown to be relevant in the development and progression of pulmonary
hypertension. Inhibition of mTOR has been shown to reverse or regress pulmonary hypertension
in animal models. ABI-009 is an albumin-bound mTOR inhibitor with improved penetration in
lung tissue.